ArticleCancer biology & medicine2023

Combined chemo-endocrine therapy as a potential new option for HR+/HER2- advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine.

Xue Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.